Replimune | Company Profile - Revenue, Headcount, Tech Stack, Contacts

Company Directory for Replimune

Replimune

Overview

Replimune Group, Inc. is a clinical-stage biotechnology company headquartered in Woburn, Massachusetts, with substantial operations in Oxfordshire, UK. Established in 2015 by experienced members of the BioVex Inc. team, it specializes in developing next-generation oncolytic immunotherapies using the proprietary Immulytic® platform for cancer treatment.

The organization’s mission is to create therapies that precisely target and destroy cancer cells while stimulating the immune system to produce an anti-tumor response. Notable achievements include advancing leading clinical candidates such as RP1, RP2, and RP3, with a strategic emphasis on combining oncolytic viruses with checkpoint inhibitors to deliver enhanced clinical outcomes.

Basic Information

Industry research
Founded 2015
Revenue 10.5M
Headquarters 500 Unicorn Park Dr., Woburn, Massachusetts, United States, 01801
Alexa Ranking 644872

Contact Details

Key Focus Areas & Initiatives

  • Development of next-generation oncolytic immunotherapies
  • Advancement of Immulytic® platform for cancer treatment
  • Clinical development of lead candidates (RP1, RP2, RP3)
  • Combination therapies with checkpoint inhibitors
  • Biotechnology research and innovation
  • Health, wellness & fitness initiatives

Technologies Used

  • AI
  • Adobe Marketing Cloud
  • Air
  • BASE
  • Barracuda Networks
  • CAT
  • Cloudflare DNS
  • Drupal
  • ElasticEmail
  • Electron
  • Elite Software HVAC Solution
  • Google Analytics
  • Google Tag Manager
  • HelpCrunch
  • ICP
  • Media Temple SSL
  • Microsoft Office
  • Microsoft Office 365
  • Mimecast
  • Mobile Friendly
  • Ning
  • Outlook
  • Remote
  • Resi
  • SAP Crystal Solutions
  • Security
  • Semrush
  • Slack
  • Thermo Scientific Chromeleon Chromatography Data System (CDS)
  • Vimeo
  • WordPress.org
  • eMaint CMMS
  • iCIMS
  • reCAPTCHA

Affiliated Organizations & Regional Branches

    Read more